{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihcqssvq5tdly7vo4bor4gap3simhlje5qdujbigftus5laak3b5i",
    "uri": "at://did:plc:eovmz6dbqbanxpynuzivgyc4/app.bsky.feed.post/3mjluiqmjxii2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieq7srp4yi2a5rayuhdu3rhbdghw7tcumlqhsqmmdzzlcf2yaj5tu"
    },
    "mimeType": "image/jpeg",
    "size": 88997
  },
  "path": "/news/health/alzheimers-drugs-review-lecanemab-donanemab-b2958258.html",
  "publishedAt": "2026-04-16T00:03:00.000Z",
  "site": "https://www.the-independent.com",
  "tags": [
    "Health",
    "News"
  ],
  "textContent": "Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK",
  "title": "Alzheimer’s drugs ‘make no meaningful difference to patients’, major review suggests",
  "updatedAt": "2026-04-16T00:03:00.000Z"
}